A long-standing member of therapeutic proteins company Ablynx has stepped down from his position as chief scientific officer and member of the executive committee.
Dr Hennie Hoogenboom first joined the Belgium-based company in 2005 and contributed to building up the Nanobody technology platform and to the discovery of Nanobodies for internal and partnered therapeutic programmes. Hoogenboom will work closely together with the executive committee to assure an effective and smooth transition of responsibilities.
Hoogenboom said: "Working at Ablynx for the past years has been an extraordinary and unique opportunity, with the Company growing from a small biotech firm to a public company with multiple large partnerships with pharmaceutical companies, I'm honored to have been part of this phase of the Company and to have worked with such talented and dedicated colleagues."
